Phaseline

Companies › ADARx Pharmaceuticals

ADARx Pharmaceuticals: clinical trials, targets and expected readouts

5 active drug programs in 10 registered trials: 4 Phase 1, 4 Phase 2, 2 Phase 3; Genitourinary, Cardiovascular, Hematology, Ophthalmology; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ADX-324
siRNA duplex oligonucleotide targeting KLKB1
KLKB1Phase 3Hereditary Angioedema; Hereditary Angioedema (HAE)Nov 2027
ADX-038
siRNA duplex oligonucleotide
–Phase 2Immunoglobulin A Nephropathy (IgAN); IgAN; Geographic Atrophy Secondary to Age-related Macular Degeneration; Paroxysmal Nocturnal Hemoglobinuria (PNH)Mar 2028
Telitacicept
fusion protein
–Phase 2Immunoglobulin A Nephropathy (IgAN)Jul 2028
ADX-626
siRNA duplex oligonucleotide
–Phase 1Healthy Adult ParticipantsJan 2027
ADX-850
siRNA duplex oligonucleotide
–Phase 1HypertensionMar 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07081503ADX-626Phase 1Healthy Adult ParticipantsOtherJan 2027
NCT06205628ADX-850Phase 1HypertensionCardiovascularMar 2027
NCT06960213ADX-324Phase 3Hereditary AngioedemaImmunologyNov 2027
NCT05691361ADX-324Phase 1Hereditary AngioedemaImmunologyDec 2027
NCT05876312ADX-038Phase 1Paroxysmal Nocturnal Hemoglobinuria (PNH)HematologyMar 2028
NCT07522099ADX-038Phase 2Immunoglobulin A Nephropathy (IgAN)GenitourinaryJul 2028
NCT07522099TelitaciceptPhase 2Immunoglobulin A Nephropathy (IgAN)GenitourinaryJul 2028
NCT06989359ADX-038Phase 2IgANGenitourinaryDec 2028
NCT06990269ADX-038Phase 2Geographic Atrophy Secondary to Age-related Macular DegenerationOphthalmologyFeb 2030
NCT07428499ADX-324Phase 3Hereditary Angioedema (HAE)ImmunologyJun 2030

From the company's SEC filings

Press releases filed as 8-K in the last year:

Targets

KLKB1 (1)

Companies with the same targets

Kyowa Kirin KalVista Pharmaceuticals BioCryst Pharmaceuticals Pharvaris Netherlands DiaMedica Therapeutics

Companies built like this

TBF Genie Tissulaire Vensica Therapeutics BioCryst Pharmaceuticals Herbarium Laboratorio Botanico Ltda YolTech Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.